Overview

ENA-001 for Opioid Induced Respiratory Depression

Status:
RECRUITING

Trial end date:
2025-11-05

Target enrollment:

Participant gender:

Summary

This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.

Phase:

PHASE1

Details

Lead Sponsor:

Enalare Therapeutics Inc.

Collaborator:

National Institute on Drug Abuse (NIDA)